XML 79 R46.htm IDEA: XBRL DOCUMENT
v3.20.4

Equity (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Notes to Consolidated Financial Statements [Abstract] |
Composition of equity | A. Composition:
| As at December 31, 2020 | As at December 31, 2019
| Authorized | Issued and paid | Authorized | Issued and paid
Number of Ordinary shares of Israeli Shekel 1 par value (in millions) | 1,485 | * 1,305 | 1,485 | * 1,305
Number of Special State share of Israeli Shekel 1 par value | 1 | 1 | 1 | 1
(*) For information regarding the amount of treasury shares, see Note 19.G.(1)
Reconciliation of the number of shares outstanding | The reconciliation of the number of shares outstanding at the beginning and at the end of the year is as follows:
| Number of Outstanding Shares (in millions)
As at January 1, 2019 | 1,305
Issuance of shares | -
As at December 31, 2019 | 1,305
Issuance of shares | -
As at December 31, 2020 | 1,305
Share-based payments to employees, non-marketable options | Non-marketable options
Grant date | Employees entitled | Number of instruments (thousands) | Issuance's details | Instrument terms | Vesting conditions | Expiration date
August 6, 2014 | Officers and senior employees | 3,993 | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan. | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. In case that on the exercise date the closing price of an ordinary share is higher than twice the exercise price (the “Share Value Cap”), the number of the exercised shares will be reduced so that the product of the exercised shares actually issued to an offeree multiplied by the share closing price will equal to the product of the number of exercised options multiplied by the Share Value Cap. | 3 equal tranches: (1) one third on December 1, 2016 (2) one third on December 1, 2017 (3) one third on December 1, 2018 | Two years from the vesting date.
December 11, 2014 | Former CEO | 367
May 12, 2015 | Officers and senior employees | 6,729 | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date | The first and second tranches is at the end of 36 months after the grant date for the third tranche is at the end of 48 months after the grant date.
June 29, 2015 | Former CEO | 530
Former chairman of BOD | 404
June 30, 2016 | Officers and senior employees | 3,035 | June 30, 2023
September 5, 2016 | Former chairman of BOD | 186
February 14, 2017 | Former CEO | 114 | February 14, 2024
June 20, 2017 | Officers and senior employees | 6,868 | June 20, 2024
August 2, 2017 | Former chairman of BOD | 165
Note 19 – Equity (cont'd) C. Share-based payments (cont'd) Non-marketable options (cont'd)
Grant date | Employees entitled | Number of instruments (thousands) | Issuance's details | Instrument terms | Vesting conditions | Expiration date
March 6, 2018 | Officers and senior employees | 5,554 | An issuance of non-marketable and non-transferrable options, for no consideration, under the 2014 Equity Compensation Plan. | Upon exercise, each option may be converted into one ordinary share of NIS 1 par value of the Company. | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date | March 6, 2025
May 14, 2018 | CEO | 385 | May 14, 2025
August 20, 2018 | Former chairman of BOD | 403 | August 20, 2025
April 15, 2019 | Officers and senior manager | 13,242 | 2 equal tranches: (1) half at the end of 24 months after the grant date. (2) half at the end of 36 months after the grant date. | 5 years after the grant date
June 27, 2019 | CEO | 3,512
May 29, 2019 * | Chairman of BOD | 2,169 | 2 equal tranches: (1) half at the end of 24 months after the issuance date. (2) half at the end of 36 months after the issuance date. | 5 years after the issuance date
* The options were issued upon Mr. Doppelt's entry into office on July 1, 2019.
Share-based payments to employees, non-marketable options, grants parameters | The fair value of the options granted in 2014, as part of 2014 equity compensation plan, as amended, was estimated using the binomial model for pricing options. The grants in 2015, 2016, 2017, 2018 and 2019 under the 2014 Equity Compensation Plan, as amended, were estimated using the Black & Scholes model for pricing options. The parameters used in applying the models are as follows:
| 2014 Plan
| Granted 2014 | Granted 2015 | Granted 2016 | Granted 2017 | Granted 2018 | Granted 2019 |
Share price (in $) | 8.2 | 7.0 | 3.9 | 4.5 | 4.4 | 5.4
CPI-linked exercise price (in $) | 8.4 | 7.2 | 4.3 | 4.3 | 4.3 | 5.3
Expected volatility: |  |  |  |  |  |
First tranche | 29.40% | 25.40% | 30.51% | 31.88% | 28.86% | 27.85%
Second tranche | 31.20% | 25.40% | 30.51% | 31.88% | 28.86% | 27.85%
Third tranche | 40.80% | 28.80% | 30.51% | 31.88% | 28.86% | 27.85%
Expected life of options (in years): |  |  |  |  |  |
First tranche | 4.3 | 3.0 | 7.0 | 7.0 | 7.0 | 4.4
Second tranche | 5.3 | 3.0 | 7.0 | 7.0 | 7.0 | 4.4
Third tranche | 6.3 | 4.0 | 7.0 | 7.0 | 7.0 | 4.4
Risk-free interest rate: |  |  |  |  |  |
First tranche | (0.17)% | (1.00)% | 0.01% | 0.37% | 0.03% | (0.67)%
Second tranche | 0.05% | (1.00)% | 0.01% | 0.37% | 0.03% | (0.67)%
Third tranche | 0.24% | (0.88)% | 0.01% | 0.37% | 0.03% | (0.67)%
Fair value (in $ millions) | 8.4 | 9.0 | 4.0 | 11.3 | 8.8 | 7.5
Weighted average grant date fair value per option (in $) | 1.9 | 1.2 | 1.1 | 1.6 | 1.4 | 1.2
Share-based payments to employees, non-marketable options, movement in the options | The movement in the options are as follows:
| Number of options (in millions)
| 2014 Plan
Balance as at January 1, 2019 | 18
Movement in 2019: |
Granted during the year | 19
Expired during the year | (3)
Forfeited during the year | (3)
Exercised during the year | (1)
Total options outstanding as at December 31, 2019 | 30
Movement in 2020: |
Expired during the year | (2)
Exercised during the year | (1)
Total options outstanding as at December 31, 2020 | 27
Share-based payments to employees, non-marketable options, exercise price | The exercise prices for options outstanding at the beginning and end of each period are as follows:
| December 31, 2020 | December 31, 2019 | December 31, 2018
Granted 2014 US Dollar | - | 7.15 | 6.77
Granted 2015 US Dollar | - | - | 6.92
Granted 2016 US Dollar | 4.56 | 4.36 | 4.21
Granted 2017 US Dollar | 4.17 | 4.01 | 3.89
Granted 2018 US Dollar | 4.12 | 3.99 | 3.89
Granted 2019 US Dollar | 5.66 | 5.42 | -
Share-based payments to employees, non-marketable options, number of options vested | The number of outstanding vested options at the end of each period and the weighted average exercise price for these options are as follows (*):
| December 31, 2020 | December 31, 2019 | December 31, 2018
Number of options exercisable (In Millions) | 11 | 12 | 11
Weighted average exercise price in Israeli Shekel | 13.89 | 15.19 | 18.53
Weighted average exercise price in US Dollar | 4.32 | 4.40 | 4.94
(*) The share price as of December 31, 2020, is NIS 16.36 and $5.09.
Share-based payments to employees, non-marketable options, range of exercise prices | The range of exercise prices for the options outstanding vested at the end of each period are as follows:
| December 31, 2020 | December 31, 2019 | December 31, 2018
Range of exercise price in Israeli Shekel | 13.15-18.32 | 13.55-24.71 | 14.26-25.93
Range of exercise price in US Dollar | 4.09-5.70 | 3.92-7.15 | 3.81-6.92
Share-based payments to employees, non-marketable options, average remaining contractual life | The average remaining contractual life for the outstanding vested options at the end of each period are as follows:
| December 31, 2020 | December 31, 2019 | December 31, 2018
Average remaining contractual life | 3.58 | 3.85 | 3.90
Share-based payments to employees, restricted shares |
Grant date | Employees entitled | Number of instruments (thousands) | Vesting conditions (*) | Instrument terms | Additional Information | Fair value at the grant date (Million)
August 6, 2014 | Officers and senior employees | 922 | 3 equal tranches: (1) one third on December 1, 2016 (2) one third on December 1, 2017 (3) one third on December 1, 2018 | An issuance for no consideration, under the 2014 Equity Compensation Plan. | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the date of the approval of the General Meeting where required). | 7.6
February 26, 2015 | ICL’s Directors (excluding ICL's CEO) | 99 | 3 tranches: (1) 50% will vest August 28, 2015 (2) 25% will vest February 26, 2017 (3) 25% will vest February 26, 2018 | 0.7
May 12, 2015 | Officers and senior employees | 1,194 | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date | 8.8
June 29, 2015 | Former chairman of the BOD | 68
December 23, 2015 | ICL’s Directors (excluding ICL's CEO & Chairman of the BOD) | 121 | 3 equal tranches: (1) one third on December 23, 2016 (2) one third on December 23, 2017 (3) one third on December 23, 2018 | 0.5
June 30, 2016 | Officers and senior employees | 990 | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date | 4.1
September 5, 2016 | Former chairman of BOD | 55
(*) Vesting of the Restricted Shares would be fully accelerated if the holder ceases to serve as a director of the Company, unless he/she ceased to hold office due to those certain circumstances regarding early termination of office or imposition of enforcement measures, as set forth in Sections 231-232a and 233(2) of the Israeli Companies Law. Note 19 – Equity (cont'd) C. Share-based payments (cont'd) Restricted shares (cont’d)
Grant date | Employees entitled | Number of instruments (thousands) | Vesting conditions (*) | Instrument terms | Additional Information | Fair value at the grant date (Million)
January 3, 2017 | ICL’s Directors (excluding ICL's Chairman of the BOD) | 146 | 3 equal tranches: (1) one third at the end of 12 months after the grant date (2) one third at the end of 24 months after the grant date (3) one third at the end of 36 months after the grant date | An issuance for no consideration, under the 2014 Equity Compensation Plan. The value includes a reduction of 5% from the value of the equity compensation, pursuant to the decision of the directors in March 2016, to reduce their annual compensation for 2016 and 2017. | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the grant date (the approval date of the BOD and/or the date of the approval of the General Meeting where required). | 0.6
February 14, 2017 | Former CEO | 38 | An issuance for no consideration, under the 2014 Equity Compensation Plan. | 0.2
June 20, 2017 | Officers and Senior employees | 2,211 | 10
August 2, 2017 | Former chairman of BOD | 53 | 0.3
January 10, 2018 | ICL’s Directors (excluding ICL's CEO & Chairman of the BOD) | 137 | 0.6
March 6, 2018 | Officers and senior employees | 1,726 | 8
May 14, 2018 | CEO | 121 | 0.6
August 20, 2018 | Former chairman of BOD | 47 | 0.2
ICL’s Directors (excluding ICL's CEO & Chairman of the BOD) | 88 | Acceleration at January 2019. | 0.4
April 23, 2020 | ICL’s Directors (excluding directors who are officers or directors of Israel Corporation Ltd.) | 177 | 3 equal tranches: (1) one third on January 1, 2021 (2) one third on January 1, 2022 (3) one third on January 1,2023 | An issuance for no consideration, under the amended 2014 Equity Compensation Plan. | The value of the restricted shares was determined according to the closing price on the TASE on the most recent trading day preceding the Grant Date (the approval date of the annual General Meeting of shareholders). | 0.6
(*) Vesting of the Restricted Shares would be fully accelerated if the holder ceases to serve as a director of the Company, unless he/she ceased to hold office due to those certain circumstances regarding early termination of office or imposition of enforcement measures, as set forth in Sections 231-232a and 233(2) of the Israeli Companies Law
Dividends distributed to the Company's Shareholders |
Board of Directors decision date to distribute the dividend | Actual date of distribution of the dividend | Gross amount of the dividend distributed (in millions of $) | Net amount of the distribution (net of the subsidiary’s share) (in millions of $) | Amount of the dividend per share (in $)
February 13, 2018 | March 14, 2018 | 70 | 69 | 0.05
May 10, 2018 | June 20, 2018 | 52 | 51 | 0.04
July 31, 2018 | September 4, 2018 | 56 | 56 | 0.04
October 31, 2018 | December 19, 2018 | 66 | 65 | 0.05
Total 2018 |  | 244 | 241 | 0.18
February 5, 2019 | March 13, 2019 | 62 | 61 | 0.05
May 7, 2019 | June 19, 2019 | 76 | 75 | 0.06
July 31, 2019 | September 24, 2019 | 74 | 73 | 0.06
November 6, 2019 | December 18, 2019 | 65 | 64 | 0.05
Total 2019 |  | 277 | 273 | 0.22
February 12, 2020 | March 18, 2020 | 23 | 23 | 0.02
May 11, 2020 | June 17, 2020 | 30 | 30 | 0.02
July 28, 2020 | September 16, 2020 | 36 | 36 | 0.03
November 11, 2020 | December 16, 2020 | 29 | 29 | 0.02
Total 2020 |  | 118 | 118 | 0.09
February 11, 2021 (after the reporting date)* | March 16, 2021 | 34 | 34 | 0.03
(*) The record date is March 3, 2021 and the payment date is March 16, 2021.

X
- References No definition available. + Details
Name: | icl_DisclosureOfDividendsDistributedToTheCompanysShareholdersExplanatory
Namespace Prefix: | icl_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | icl_DisclosureOfNonMarketableOptionsAverageRemainingContractualLifeExplanatory
Namespace Prefix: | icl_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | icl_DisclosureOfNonMarketableOptionsExercisePriceExplanatory
Namespace Prefix: | icl_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | icl_DisclosureOfNonMarketableOptionsNumberOfOptionsVestedExplanatory
Namespace Prefix: | icl_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | icl_DisclosureOfNonMarketableOptionsRangeOfExercisePricesExplanatory
Namespace Prefix: | icl_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | icl_DisclosureOfSharebasedPaymentsToEmployeesNonMarketableOptionsExplanatory
Namespace Prefix: | icl_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | icl_DisclosureOfSharebasedPaymentsToEmployeesRestrictedSharesExplanatory
Namespace Prefix: | icl_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | icl_NotesToConsolidatedFinancialStatementsAbstract
Namespace Prefix: | icl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of classes of share capital. [Refer: Share capital [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 79 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of defined benefit plans. [Refer: Defined benefit plans [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 19 -IssueDate 2020-01-01 -Paragraph 138 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2020-en-r&anchor=para_138&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for share capital, reserves and other equity interest. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 79 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for share-based payment arrangements. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 44 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_44&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration